Scientist and Lecturer
email@example.com • Heller-Brown Building • 250 • 781-736-3945
Prescription drug misuse, abuse, and diversion, with a particular emphasis on state prescription drug monitoring programs and the use of their data for public health surveillance and evaluation. Program evaluation, especially in substance abuse prevention and treatment; Interagency network analysis; Small area measures and models
- Thomas, C., Kim, M., Kelleher, S., Nikitin, R., Kreiner, P., McDonald, A., & Carrow, G.. "Early experience with electronic prescribing of controlled substances in a community setting." Journal of the American Medical Informatics Association doi: 10.1136/amiajnl-2012-001499. (2013). (forthcoming)
- Thomas, C., Kim, M., McDonald, A., Kreiner, P., Kelleher, S., Blackman, M., Kaufman, P., & Carrow, G. "Prescribers’ expectations and barriers to electronic prescribing of controlled substances.." Journal of the American Medical Informatics Association doi:10.1136/amaiamnl-2011-000209. (2011). (forthcoming)
- Kreiner, P. Nikitin, R., & Shields, T.P.. Bureau of Justice Assistance Prescription Drug Monitoring Program Performance Measures Report: January, 2009 through June, 2012. Washington, DC U.S. Department of Justice, Bureau of Justice Assistance: 2013.
- Kreiner, Peter. "How prescription drug monitoring programs can help address the opioid epidemic." Workers' Compensation Research Institute Annual Conference. Cambridge, MA. February 27, 2013.
- Clark, T., Eadie, J., Kreiner, P., & Strickler, G.. Prescription Drug Monitoring Programs: An Assessment of the Evidence for Best Practices. Washington, DC Pew Charitable Trusts (http://www.pewhealth.org/uploadedFiles/PHG/Content_Level_Pages/Reports/PDMP_Full%20and%20Final.pdf): 2012.
- Kreiner, Peter. "Geospatial analyses of opioid overdose rates and rates of questionable activity in Massachusetts." National Rx Abuse Summit. Orlando, FL. April 10-12, 2012.
- Kreiner, Peter. "Prescription monitoring programs: An important new area for evaluation and a vastly underutilized data resource." American Evaluation Association Conference. Minneapolis, MN. October 25, 2012.
- Kreiner, Peter. "Non-medical prescription drug use and market intervention: Prescription drug monitoring program data and law enforcement." National Institutes of Justice Annual Conference. Washington, DC. June 22, 2011.
- Katz, N., Panas, L., Kim, M., Audet, A., Bilansky, A., Eadie, J., Kreiner, P., Paillard, F., Thomas, C., & Carrow, G.. "Usefulness of prescription monitoring programs for surveillance – analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006." Pharmacoepidemiology and Drug Safety 19. (2009): 115-123.
- Katz, N., Houle, B., Fernandez, K., Kreiner, P., Thomas, C., Kim, M., Carrow, G., Audet, A., & Brushwood, D.. "Update on prescription monitoring in clinical practice: A survey study of prescription monitoring program administrators." Pain Medicine 9. 5 (2008): 587-594.
- Markoff, L., Finkelstein, N., Kammerer, N., Kreiner, P., & Prost, C.. "Relational systems change: Implementing a model of change in integrating services for women with substance abuse and mental health disorders and histories of trauma." Journal of Behavioral Health Services and Research 32. 2 (2005): 227-240.
- Kreiner, P., Soldz, S., Berger, M., Elliott, E., Reynes, J., Williams, C., & Rodriguez-Howard, M.. "Social indicator-based measures of substance abuse consequences, risk, and protection at the town level." Journal of Primary Prevention 22. 3 (2001): 339-365.
- Soldz, S., Kreiner, P., Clark, T., & Krakow, M.. "Tobacco use among Massachusetts youth: Is tobacco control working?." Preventive Medicine 31. (2000): 287-295.
- Kreiner, P. & Bhambri, A.. "Influence and information in organization-stakeholder relationships." Research in Corporate Social Performance and Policy 12. (1991): 3-36.
Peter Kreiner, Ph.D., is a Scientist at the Schneider Institute for Health Policy, Brandeis University. His research encompasses five overlapping areas: (1) prescription drug monitoring programs, methods and tools for evaluating them and identifying best practices; (2) uses of prescription drug monitoring program data for public health surveillance and evaluation; (3) inter-organizational and interpersonal networks, and their roles in health services coordination and, more generally, state and community health infrastructures; (4) diffusion of innovation, including the adoption of evidence-based programs by substance abuse prevention and treatment agencies; and (5) small area measures and models of health-related and social problems, risk for such problems, and protection from such problems.
University of Southern California